Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

ASTRAZENECA PLC (AZN)

94
Delayed Quote. Delayed London Stock Exchange - 02/27 11:35:04 am
4469.5 GBp   +0.10%
07:14aDJASTRAZENECA : to Invest $40 Million in New Antibiotic R&D Firm
05:23a ASTRAZENECA : To Spin-out Early Stage Anti-Infectives R&D Company
03:21a AstraZeneca to carve out antibiotic R&D into separate firm
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK Health Watchdog Backs Lung Cancer Drug From Roche

05/09/2012 | 07:16pm US/Eastern

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
React to this article
Latest news on ASTRAZENECA PLC
07:14aDJASTRAZENECA : to Invest $40 Million in New Antibiotic R&D Firm
05:23a ASTRAZENECA : To Spin-out Early Stage Anti-Infectives R&D Company
03:21a AstraZeneca to carve out antibiotic R&D into separate firm
02/26 ASTRAZENECA : Company blames heat for why nasal spray flu vaccine didn't work we..
02/26 ARDELYX : Reports Fourth Quarter and Full Year 2014 Financial Results
02/26 Charles River Laboratories Announces Planned Management Changes
02/26 ASTRAZENECA : US District Court decision in PULMICORT RESPULES® (budesonide inha..
02/26 ACTAVIS : Launches Generic Pulmicort RESPULES®
02/25 ASTRAZENECA : Enters Collaboration Deal With Orca Pharmaceuticals
02/25 ASTRAZENECA : *jpmorgan cuts astrazeneca price target to 4300 pence - 'neutral'
Advertisement
Chart
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF